Stable bilayer tablet compositions
AssigneeHetero Labs Limited
InventorsParthasaradhi Reddy BANDI, Khadgapathi Podile, Sunil Deviprasad Tiwari, Srinivasa Rao Gella
Life of this patent
Estimating the term…
Abstract
The invention relates to stable bilayer tablet compositions comprising empagliflozin, linagliptin and pharmaceutically acceptable excipients which show no incompatibilities and the compositions having good stability and superior dissolution profile.
Claims11
1-10. (canceled)
A stable bilayer tablet composition comprising:
- (i) 10 mg to 25 mg of empagliflozin;
- (ii) 5 mg of linagliptin;
- and
- (iii) at least one pharmaceutically acceptable excipient;
- wherein the amount of empagliflozin is 1% to 20% (w/w) based on total weight of the composition and the amount of linagliptin is 1% to 10% (w/w) based on total weight of the composition.
The composition according to claim 1, comprising:
- (i) 10 mg of empagliflozin;
- (ii) 5 mg of linagliptin;
- and
- (iii) at least one pharmaceutically acceptable excipient;
- wherein the amount of empagliflozin is 3% to 10% (w/w) based on total weight of the composition and the amount of linagliptin is 1% to 6% (w/w) based on total weight of the composition.
The composition according to claim 1, comprising:
- (i) 25 mg of empagliflozin;
- (ii) 5 mg of linagliptin;
- and
- (iii) at least one pharmaceutically acceptable excipient;
- wherein the amount of empagliflozin is 8% to 16% (w/w) based on total weight of the composition and the amount of linagliptin is 1% to 6% (w/w) based on total weight of the composition.
The composition according to claim 1, wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of microcrystalline cellulose, lactose monohydrate, and croscarmellose sodium.
A stable bilayer tablet composition comprising:
- (i) empagliflozin;
- (ii) linagliptin;
- (iii) 5% to 30% (w/w) of microcrystalline cellulose;
- (iv) 10-40% (w/w) of lactose monohydrate;
- and
- (v) 0.5% to 5% (w/w) of croscarmellose sodium based on total weight of the composition.
The composition according to claim 5, wherein
- (i) the amount of microcrystalline cellulose is 10% to 25% (w/w) based on total weight of the composition;
- and
- (ii) the amount of lactose monohydrate is 20% to 30% (w/w) based on total weight of the composition.
The composition according to claim 1, wherein the composition exhibits dissolution of more than 85% of empagliflozin and linagliptin within 15 minutes in a dissolution test using USP paddle type dissolution apparatus.
The composition according to claim 1, wherein the composition is an immediate release tablet.
The composition according to claim 1, wherein the composition is prepared by wet granulation method.
A stable bilayer tablet composition comprising:
- (i) 10 mg to 25 mg of empagliflozin;
- and
- (ii) 5 mg of linagliptin;
Dependencies are inferred from the claim text.